COVID-19 and PTSD: Assessing the Pandemic’s Toll on Mental Health
As researchers and clinicians continue to grapple with the psychological fallout from COVID-19, a growing body of literature has examined the prevalence of post-traumatic stress disorder (PTSD) in the general public. Women’s Health Research at Yale and its collaborators published a study questioning how these estimates vary so greatly and if such wide swaths of the public can truly be suffering from pandemic-related PTSD.
SLEEP-SMART Intervention Shows Promising Results for Women Suffering from Sleeping Problems, Depression, and Anxiety
Preliminary data indicate SLEEP-SMART can improve sleep patterns, show associated reductions in symptoms of depression and anxiety, and improve the functioning of brain circuits important in emotional and cognitive health.
WHRY Funds Study on Psychological Resilience in COVID-19 Health Care Providers
Women’s Health Research at Yale announced funding for a new collaborative study with researchers at Mt. Sinai Medical Hospital in New York on the personal and professional stressors and coping strategies of frontline health care providers confronting the COVID-19 pandemic
Four Yale Researchers Honored at the 2022 Association for Clinical and Translational Science Awards
The collaboration that advanced the discovery of ketamine as a treatment for depression was among four Yale award winners at the Association for Clinical and Translational Science (ACTS) annual meeting held in Chicago from April 20 through 22.
Helping Our Students Achieve ‘Post-Traumatic Growth’
At any point in time, 1 in 5 children under the age of 18 are in need of behavioral-health services, and 80 percent of those children do not have access to the care they need. These numbers are now higher. Since the end of March 2020, nationwide and around the world, behavioral-health visits to emergency rooms for issues including anxiety, depression, and suicidality among children have been climbing steadily.Source: Education Week
Don't Jump for Joy over New FDA-approved Postpartum Depression Medicine Yet
Kimberly Yonkers, MD, Professor of Psychiatry, of Epidemiology (Chronic Diseases) and of Obstetrics, Gynecology, and Reproductive Sciences cautions new mothers who may consider taking the new FDA-approved medication for postpartum depression in an opinion piece published in USA Today.Source: USA Today
FDA Approves First Postpartum Depression Drug, but Access Is an Issue
Kimberly Yonkers, MD, Professor of Psychiatry, of Epidemiology (Chronic Diseases) and of Obstetrics, Gynecology, and Reproductive Sciences, speaks to NPR about the U.S. Food and Drug Administration's approval of Zulresso, the first drug specifically for postpartum depression.Source: NPR
Yale Psychiatrists, Pioneers of Ketamine Research, Shed Light on Depression Drug
John H. Krystal, MD, and Gerard Sanacora, MD, PhD, of the Yale Department of Psychiatry share their views on the Food and Drug Administration approval of the drug esketamine to treat major depression.Source: Yale Medicine